Detalhe da pesquisa
1.
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Br J Haematol
; 183(4): 601-607, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30596402
2.
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Am J Hematol
; 90(6): 483-6, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25689471
3.
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Haematologica
; 104(4): e143-e146, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30409798
4.
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.
Br J Haematol
; 161(2): 183-91, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23356514
5.
Changing the treatment paradigm in myelodysplastic syndromes.
Cancer Control
; 15 Suppl: 14-28, 2008 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-18813206
6.
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.
Leukemia
; 32(11): 2352-2362, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29720734
7.
Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.
Leuk Lymphoma
; 54(11): 2534-6, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23432687